dc.contributor.author | Van de Water, Sandra G.P. | |
dc.contributor.author | Potgieter, Christiaan A. | |
dc.contributor.author | Van Rijn, Piet A. | |
dc.contributor.author | Van Gennip, René G.P. | |
dc.contributor.author | Wright, Isabel M. | |
dc.date.accessioned | 2016-09-21T07:09:07Z | |
dc.date.available | 2016-09-21T07:09:07Z | |
dc.date.issued | 2015 | |
dc.identifier.citation | Van de Water, S.G.P. et al. 2015. VP2 exchange and NS3/NS3a deletion in African Horse Sickness Virus (AHSV) in development of disabled infectious single animal vaccine candidates for AHSV. Journal of virology, 89(17):8764-8772. [http://dx.doi.org/10.1128/JVI.01052-15] | en_US |
dc.identifier.issn | 0022-538X | |
dc.identifier.issn | 1098-5514 (Online) | |
dc.identifier.uri | http://hdl.handle.net/10394/18851 | |
dc.identifier.uri | http://dx.doi.org/10.1128/JVI.01052-15 | |
dc.identifier.uri | http://jvi.asm.org/content/89/17/8764 | |
dc.description.abstract | African horse sickness virus (AHSV) is a virus species in the genus Orbivirus of the family Reoviridae. There are nine serotypes of
AHSV showing different levels of cross neutralization. AHSV is transmitted by species of Culicoides biting midges and causes
African horse sickness (AHS) in equids, with a mortality rate of up to 95% in naive horses. AHS has become a serious threat for
countries outside Africa, since endemic Culicoides species in moderate climates appear to be competent vectors for the related
bluetongue virus (BTV). To control AHS, live-attenuated vaccines (LAVs) are used in Africa. We used reverse genetics to generate
“synthetic” reassortants of AHSV for all nine serotypes by exchange of genome segment 2 (Seg-2). This segment encodes VP2,
which is the serotype-determining protein and the dominant target for neutralizing antibodies. Single Seg-2 AHSV reassortants
showed similar cytopathogenic effects in mammalian cells but displayed different growth kinetics. Reverse genetics for AHSV
was also used to study Seg-10 expressing NS3/NS3a proteins. We demonstrated that NS3/NS3a proteins are not essential for
AHSV replication in vitro. NS3/NS3a of AHSV is, however, involved in the cytopathogenic effect in mammalian cells and is very
important for virus release from cultured insect cells in particular. Similar to the concept of the bluetongue disabled infectious
single animal (BT DISA) vaccine platform, an AHS DISA vaccine platform lacking NS3/NS3a expression was developed. Using
exchange of genome segment 2 encoding VP2 protein (Seg-2[VP2]), we will be able to develop AHS DISA vaccine candidates for
all current AHSV serotypes | en_US |
dc.language.iso | en | en_US |
dc.publisher | American Society for Microbiology | en_US |
dc.title | VP2 exchange and NS3/NS3a deletion in African Horse Sickness Virus (AHSV) in development of disabled infectious single animal vaccine candidates for AHSV | en_US |
dc.type | Article | en_US |
dc.contributor.researchID | 10085637 - Potgieter, Abraham Christiaan | |
dc.contributor.researchID | 24551287 - Van Rijn, Petrus Antonius | |